Immunovant, Inc.
IMVT US
IMVT USImmunovant, Inc.
United States CompositeCompany Description
- CEO
- Dr. Peter Salzmann M.B.A., M.D.
- Full Time Employees
- 164
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 320 West 37th Street New York NY United States 10018
- IPO Date
- Jun 21, 2019
- CIK
- 0001764013
- Website
- immunovant.com
- Business
- Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.